Requirements for distinct steps of phospholipase C*γ* **2 regulation, membrane-raft-dependent targeting and subsequent enzyme activation in B-cell signalling**

Rosie RODRIGUEZ, Miho MATSUDA, Amy STOREY and Matilda KATAN¹

Cancer Research UK Centre for Cell and Molecular Biology, Chester Beatty Laboratories, The Institute of Cancer Research, Fulham Road, London SW3 6JB, U.K.

Studies of PLC*γ* (phospholipase C*γ*) have identified a number of regulatory components required for signalling; however, molecular mechanisms and the relationship between events leading to translocation and an increase of substrate hydrolysis have not been well defined. The addition of a membrane-targeting tag to many signal transducers results in constitutive activation, suggesting that these processes could be closely linked and difficult to dissect. The present study of PLC*γ* 2 regulation by cross-linking of the BCR (B-cell antigen receptor) or H_2O_2 stress in DT40 Bcells, demonstrated that the membrane targeting is a separate step from further changes that result in enzyme activation and substrate hydrolysis. Furthermore, we have defined the roles of different domains of PLC*γ* 2 and, using a panel of cell lines deficient in components linked to PLC*γ* 2 regulation, the involvement of signalling molecules with respect to each of the steps. We have found that only the lipid-raft-targeted Lyn–PLC*γ* 2 construct, unlike nonspecific membrane targeting, overcame the requirement for the

INTRODUCTION

The hydrolysis of PtdIns $(4,5)P_2$ by PI-PLC (phosphoinositidespecific phospholipase C) occurs in response to a large number of extracellular signals (reviewed in [1–3]). Four families of mammalian PI-PLC, PLC*β* (*β*1–*β*4), PLC*γ* (*γ* 1 and *γ* 2), PLC*δ* (*δ*1– *δ*4) and PLC*ε*, have been described. Each family is characterized by the distinct domain organization and type of signalling pathways that regulate enzyme activity.

PLC*γ* isoforms are mainly regulated through receptors with intrinsic tyrosine kinase activity (e.g. growth factor receptors) or receptors [such as BCR and TCR (B- and T-cell antigen receptors respectively)] that are linked to the activation of nonreceptor tyrosine kinases through a complex signalling network [1–4]. Regulation of PLC*γ* 1 by growth factor receptors, where the receptor provides the main membrane-binding partner and the tyrosine kinase acting on PLC*γ* , has been studied extensively. The extent to which production of PtdIns $(3,4,5)P_3$ also contributes to stimulation of PLC*γ* 1 by the tyrosine kinase receptors varies depending on the cell system and the type of receptor [5–7]. Other signalling components may also be involved in regulation of growth-factor-triggered PLC*γ* 1 activity; for example, recent data have implied that c-Cbl has a direct interaction with PLC*γ* 1 [8]. Studies of PLC*γ* isoforms in haematopoietic cells, in particular PLC*γ* 1 signalling in response to the cross-linking of TCR and PLC*γ* 2 signalling following stimulation of BCR, revealed adapter protein BLNK (B-cell linker). The stable expression of Lyn–PLC γ ² was not accompanied by an increase in substrate hydrolysis in resting cells, which followed stimulation and specifically required the presence and/or activation of Syk, Btk, phosphoinositide 3-kinase but not BLNK, as established using deficient cell lines or specific inhibitors. Based on mutational analysis of the specific tyrosine residues $[Tyr^{753} \rightarrow Phe (Y753F)/$ Y759F] and SH2 (Src homology 2) domains (R564A/R672A) in the context of Lyn–PLC γ 2, we found that Tyr⁷⁵³/Tyr⁷⁵⁹ were essential, whereas the PLC γ 2 SH2 domains did not have an important role in the transient activation of Lyn–PLC*γ* 2 but may serve to stabilize an activated form in sustained activation.

Key words: B-cell signalling, membrane raft, phospholipase activation, phospholipase C*γ* 2 (PLC*γ* 2), Src homology 2 domain (SH2 domain), tyrosine phosphorylation.

some general similarities in the type of components required for regulation of PLC activity in these more complex systems [9– 11]. The involvement of non-receptor protein tyrosine kinases, such as Src, Syk/Zap70 and Tec families, cell-type specific adapter proteins, PI3K (phosphoinositide 3-kinase) and members of Cbl family, is either critical or plays a role in regulation of intensity and duration of $PtdIns(4,5)P_2$ hydrolysis. Based on studies in DT40 cells and several other B-cell lines, the signalling components in B-cells involved in regulation of PLC*γ* 2 include the tyrosine kinases Lyn, Syk and Btk, PI3K and an adapter protein BLNK (B-cell linker); it has been suggested that BLNK provides a direct interacting partner and that Btk could be directly involved in phosphorylation of critical tyrosine residues in PLC*γ* 2 [10,11].

A further level of complexity in regulation of PLC*γ* isoforms may be provided by specific membrane targeting to the lipid rafts, also known as glycolipid-enriched microdomains. There is evidence suggesting the importance of the integrity of these specific microdomains in EGF (epidermal growth factor) receptor stimulation of PLC*γ* 1 [12]. However, the function of lipid rafts have been more extensively studied in B- and T-cells [9,13], with the data generally supporting formation of BCR- and TCRsignalling complexes in this structure, which may also regulate cross-talk between different receptors (e.g. BCR and CD19 in B-cells). Although several reports suggest that the presence of raft structures in the plasma membrane seem to be required for

Abbreviations used: BCR, B-cell antigen receptor; BLNK, B-cell linker; EGF, epidermal growth factor; Fluo 3/AM, Fluo-3 acetoxymethyl ester; PH, pleckstrin homology; PH*δ*1PLC*γ*2, chimera of PLC*γ*2 containing PLC*δ*1 PH domain; PI3K, phosphoinositide 3-kinase; PI-PLC, phosphoinositide-specific phospholipase C; SH2 and SH3, Src homology 2 and 3 respectively; TCR, T-cell antigen receptor; Y753F etc., Tyr⁷⁵³ \rightarrow Phe substitution etc. ¹ To whom correspondence should be addressed (matilda@icr.ac.uk).

PLC γ -mediated signalling [14,15], this signalling may not be confined to the rafts and, in the case of signalling by BCR crosslinking, the raft targeting could be dependent on the stage in B-cell development [16,17].

In contrast with extensive information regarding signalling networks involved in the regulation of PLC*γ* isoforms by receptor and non-receptor tyrosine kinases, the precise mechanism of transition from an inactive to active form of PLC*γ* remains unclear. Nevertheless, one requirement that has been defined in both systems is translocation of PLC*γ* isoforms to the plasma membrane. Studies in growth-factor-stimulated cells demonstrated the role of the SH2 (Src homology 2) domains of PLC*γ* as a driving force for the translocation to the plasma membrane, which is mediated by direct interaction with the receptor [12,18]. Similarly, the requirements for the PLC*γ* 2 SH2 domains and interaction with BLNK have been shown in B-cells following BCR cross-linking [19–21]. Interestingly, the recruitment of PLC*γ* 1 to signalling complex in T-cells involves interactions with two adapter proteins [Slp-76 (SH2 domain containing leucocyte protein of 65 kDa) and Lat (linker for activation of T-cell)] and requires the SH2 and SH3 domains of PLC*γ* 1 [4]. There is also evidence that in some systems PI3K can indirectly or directly support translocation [5,22]. While the translocation is clearly important, other changes, most notably phosphorylation of specific tyrosine residues, are involved in stimulation of PLC γ isoforms [23–25]. Other ways of stimulation of PLC*γ* that do not involve tyrosine phosphorylation have also been suggested [26]. There are several lines of experimental evidence (including limited proteolysis and peptide inhibition) suggesting that an intramolecular inhibitory constraint is imposed by regions within the PLC*γ* -specific domain array [*γ* SA, comprising the 'split' PH (pleckstrin homology) domain, two SH2 domains and one SH3 domain] [27–29]. Therefore, it could be speculated that phosphorylation of essential tyrosine residues in this region (e.g. Tyr⁷⁸³ in PLC γ 1 and Tyr⁷⁵³ and Tyr759 in PLC*γ* 2) and/or other interactions with the SH2 or SH3 domains could result in conformational changes that overcome this intramolecular inhibition. Another area where experimental evidence is lacking concerns the relationship between translocation and changes that could result in an increase of substrate hydrolysis, in particular, whether these could, at least in part, be mediated by the same interactions. Specifically, in B-cells signalling components, such as BLNK, could be involved in both translocation and activation of PLC*γ* 2. Similarly, some domains of PLC*γ* 2 (e.g. SH2 domains) could be involved in both processes.

In the present study we have described further insights into PLC*γ* 2 signalling in DT40 B-cell lines following either BCR cross-linking or exposure to H_2O_2 , which are known to trigger similar signalling pathways [30–32]. Since it has been reported that PLC γ ² signalling in B-cells could be either stimulated [14] or inhibited [33] by the formation of lipid-raft structures and that BCR signalling could also take place outside lipid rafts in immature B-cells [17], it was important to directly examine the ability of different regions of the plasma membrane to sustain PLC γ ² signalling. We have found that the raft targeting is essential for the BCR and also for stress-induced $\text{Ins}(1,4,5)P_3$ production in DT40 B-cell line.

When the localization to rafts was achieved using the targeting sequence from Src family kinase Lyn, the activation of Lyn– PLC*γ* 2 almost completely overcame the requirement for BLNK. This targeting, not accompanied by an increase in substrate hydrolysis, suggested that it represents a separate step from the stimulation of PLC activity, and therefore enabled further studies of the interactions specifically required for the activation of targeted PLC γ 2, which have been difficult to address in previous studies of PLC*γ* isoforms. While BLNK was clearly not required for

the activation, we have found that this step, when triggered by the cross-linking of BCR, involves stimulation of Syk, Btk and PI3K; the requirement for these components was less stringent in H_2O_2 induced stress responses. We have also found that the PLC*γ* 2 SH2 domains did not have an important role in transient activation of the raft-targeted Lyn–PLC γ ², which is in contrast with specific tyrosine residues (Tyr^{753}) and $Tyr^{759})$ that were essential for both BCR cross-linking and H_2O_2 -induced responses.

EXPERIMENTAL

Constructs for expression in DT40 B-cells

For the expression of wild-type human PLC*γ*2 in DT40 (chicken B-lymphoma) cell line, the full-length cDNA of PLC*γ* 2 was subcloned into the pApuro vector to generate the previously described pApuroPLC*γ* 2 construct [18]. The chimera PH*δ*1PLC*γ* 2, encoding amino acids 1–134 from rat PLC*δ*1 and residues 134–1265 from human PLC*γ* 2, was generated using the two-stage PCR-based extension method. The PCR fragment, encoding the N-terminal portion of the chimera, was subcloned into a vector generated by EcoRI cleavage of pAPuroPLC*γ* 2 to produce pAPuroPH*δ*1PLC*γ* 2 plasmid. The two-stage PCR approach was also used to generate construct incorporating 9 amino acids from the N-terminus of the Src kinase Lyn (G2 CIKSKGKD10) between the first and second amino acids residues of PLC*γ* 2. The PCR fragment incorporating this Lyntag was subcloned into pAPuroPLC*γ* 2, using unique *Eco*RI sites, generating pAPuroLyn-PLC*γ* 2. This PCR fragment was also subcloned into a plasmid encoding PLC*γ* 2 with mutations of two critical tyrosine residues, pAPuroPLC*γ* 2Y753F*/*Y759F (where Y753F is the substitution Tyr⁷⁵³ \rightarrow Phe etc.) [24], creating a Lyn-tag at the N-terminus of the construct (pAPuroLyn-PLC*γ* 2^{Y753F}/Y759F). To generate pAPuroLyn-PLC_γ 2^{R564A/R672A}, where mutations are introduced into the N- and C-terminal SH2 domains in the context of Lyn–PLC*γ* 2, the following strategy was used. First, pAPuroPLC*γ* 2R564A*/*R672A was made by subcloning the entire coding region from pVL1393PLC $γ$ 2^{R564A/R672A} (the mutations were generated as described in [18]) into pAPuro, using *Kpn*I and blunt-ended *Eco*RI restriction sites. The PCR fragment incorporating the Lyn-tag was subsequently subcloned into pAPuroPLC*γ* 2R564A*/*R672A using the same strategy as described for pAPuroLyn-PLC*γ* 2. A fragment incorporating sequence of human BLNK was subcloned into pApuro from a previously described plasmid [24], using *Kpn*I and blunt-ended *Bam*HI restriction sites.

Generation of stable D40 cell lines

DT40 cells (the wild-type and PLC*γ* 2-, BLNK-, Btk- and Sykdeficient) were maintained in RPMI 1640 medium, supplemented with 10% (v/v) foetal bovine serum (Gibco), 1% (v/v) chicken serum (Gibco) and 3 mM glutamine, in the presence of 5% CO2 at 40 *◦*C. Stable transfectants of DT40 cells were generated as described previously [18,24]. Briefly, various PLC*γ* 2 and BLNK constructs in pApuro were linearized and introduced into DT40 cell lines (PLC*γ* 2-, BLNK-, Syk- or Btk- deficient) by electroporation (950 V, 25 μ F, ∞ Ω ; Gene Pulser, Bio-Rad Laboratories). After 24 h, puromycin (0.35 *µ*g/ml for PLC*γ* 2 deficient and 0.29 *µ*g/ml for BLNK-, Syk- and Btk-deficient cells) was added to the medium. After the selection (10–12 days), colonies were isolated and puromycin $(0.3 \mu g/ml)$ selection repeated for 5–8 days. Subsequently, the puromycin-resistant colonies were grown in normal medium for a further 6 days. Generated stable cell lines are listed in Table 1.

Measurements of Ca²⁺ responses and $\text{Ins}(1,4,5)P_3$ **production**

Intracellular Ca^{2+} concentrations in DT40 cells were measured using fluorescence spectroscopy, essentially as described previously [18,24]. Briefly, a cell suspension of 5×10^6 cells was loaded with 2 *µ*M Fluo 3/AM (Fluo-3 acetoxymethyl ester) (Molecular Probes) in RPMI 1640 medium for 1 h at 20 *◦* C. The cells were washed with PBS, resuspended in RPMI 1640 medium and stimulated with 10 μ g/ml M4 antibody or 2 mM H₂O₂ and their Ca2⁺ mobilization simultaneously measured at 40 *◦*C, with constant stirring in a LPS-220B fluorimeter (Photon Technology International). Excitation wavelength was at 490 nm and emission was monitored at a wavelength of 535 nm. The responses were quantitated as described previously in [18,24], taking into account the area of the peak corresponding to immediate rise in Ca^{2+} concentrations.

Production of $Ins(1,4,5)P_3$ was measured using BIOTRAK IP₃ assay system (Amersham Pharmacia Biotech) or Inositol-1,4,5- Triphosphate [3 H] Radioreceptor Assay Kit (NEN), according to the manufacturers' instructions. For these measurements, aliquots of DT40 cells (2×10^6) were used, resuspended in 50 μ l of culture medium and stimulation carried out with $10 \mu g/ml$ M4 or $2 \text{ mM } H_2O_2$ at 37 °C for the time indicated in the Figure legends. The incubation was stopped with 50 μ l of ice-cold 15% (w/v) trichloroacetic acid. After centrifugation at 5000 rev./min for 15 min, the supernatants were washed four times with 1 ml of water-saturated diethyl-ether and used for $\text{Ins}(1,4,5)P_3$ mass measurements with the reagents supplied by the manufacturers.

For experiments using the PI3K inhibitors LY294002 (Calbiochem) and wortmannin (Calbiochem), DT40 cells were loaded with 2 *μ*M Fluo 3/AM for 30 min at 40 °C (for Ca²⁺ measurements only) and incubated with 50 *µ*M LY294002 or 100 nM wortmannin for a further 30 min. Cells were then stimulated with 2 mM H₂O₂ or 10 μ g/ml M4. Intracellular Ca²⁺ mobilization and $Ins(1,4,5)P_3$ production was measured as described above.

Analysis of cellular localization and phosphorylation of different PLC*γ* **2 constructs**

Localization of PLC*γ* 2 protein in various DT40 cell lines was performed by immunostaining. The cells were fixed in 4% (v/v) paraformaldehyde for 10 min, washed with PBS for 2 min and permeabilized with 0.1% (v/v) Triton X-100, 100 mM glycine in PBS for 15 min. Permeabilized cells were incubated with 10% (v/v) foetal calf serum for 30 min. Localization of PLC*γ* 2 in cells was visualized using a polyclonal anti-PLC*γ* 2 antibody (Santa Cruz Biotechnology, dilution 1:2000). After 1 h, cells were washed with PBS and incubated with FITC-labelled goat anti-rabbit antibody (Pharmingen; dilution 1:200) for 30 min.

Cell fractionation and preparation of the lipids rafts (glycolipidenriched membranes) was based on previously published methods [34,35]. DT40 cells (3×10^7) were resuspended in 200 μ l of lysis buffer (60 mM Tris/HCl, pH 8.0, 150 mM NaCl, 5 mM EDTA, 1 mM Na₃VO₄, protease and phosphatase inhibitors) without detergent, and sonicated three times with 5-s pulses. Samples were adjusted to a total volume of 1 ml in lysis buffer containing 1% (w/v) Brij 58 (Sigma) and maintained on ice for 1 h. The lysates were then mixed with 85% (w/v) sucrose in 60 mM Tris/HCl (pH 8.0), containing 150 mM NaCl and 5 mM EDTA (pH 8.0) and transferred to polyallomer centrifuge tubes (Beckman). A 2-ml volume of 30% (w/v) sucrose was layered on top, followed by 1 ml of 5% (w/v) sucrose. Samples were subjected to centrifugation in a SW55Ti rotor at 200 000 *g* for 16 h at $4 °C$. Fractions $(400 \,\mu\text{I})$ were collected from the top of the gradient and $40 \mu l$ aliquots were analysed by Western blotting. Alternatively, for comparison of non-stimulated and stimulated cells, starting from 1×10^8 cells, the fractions containing the raft-marker Lyn were pooled and concentrated prior to analysis by Western blotting. For detection of PLC*γ* 2, the anti-PLC*γ* 2 antibody (1:4000; Santa Cruz Biotechnology) was used, whereas chicken Lyn present in DT40 cells was visualized using anti-chicken Lyn antibodies (1:2000; a gift from T. Kurosaki, Department of Molecular Genetics, Institute for Liver Research, Kansai Medical University, Japan). After incubation with the secondary antibody (donkey anti-rabbit antibody, dilution 1:4000; Amersham Pharmacia Biotech), the visualization was performed using the enhanced chemiluminescence (ECL^{\circledR}) system (Amersham Pharmacia Biotech).

Analysis of PLC*γ*2 tyrosine phosphorylation was performed essentially as previously described [18,24]. Typically, a sample of 6×10^6 cells from various DT40 cell lines was stimulated with $2 \text{ mM } H_2O_2$ at 37 °C for $4-5 \text{ min }$ or with $10 \mu\text{g/ml } M4$ antibody for 1–3 min. The cell pellet was resuspended in 200 μ l of lysis buffer [1% (v/v) Triton, 150 mM NaCl, 10 mM Tris, pH 7.4, 1 mM EDTA, 1 mM EGTA, 0.2 mM Na₃VO₄, 0.5% (v/v) Nonidet P40, protease inhibitor cocktail (Roche), and phosphatase inhibitor cocktail (Sigma)] and the cells were lysed by incubation for 30 min at 4 *◦* C. The supernatant was removed and added to anti-PLC*γ* 2 antibody–Protein G complexes and incubated at 4 *◦*C for 1.5 h. After the incubation, immunocomplexes were washed with lysis buffer, resuspended in SDS gel-loading buffer and subjected to SDS/PAGE (7.5% polyacrylamide gels) and then Western blotting. For the detection of PLC*γ* 2, the anti- $PLC\gamma$ ² antibody was used as described above. The detection of PLC*γ* 2 phosphorylation was performed using antiphosphotyrosine antibody (1:1000; Transduction Laboratories) and the secondary antibody (goat anti-mouse Ig-horseradishperoxidase-linked whole antibody from Amersham Pharmacia Biotech; diluted 1:3000). The visualization was performed by enhanced chemiluminescence and the intensity of selected areas assessed using NIH Image 1.62 program.

RESULTS

Constitutive membrane targeting of PLC*γ* **2 in DT40 cells**

Following stimulation in a number of cellular systems, PLC*γ* 1 and PLC γ ² translocate to the plasma membrane. In analysis

Figure 1 Localization of the wild-type, PLC*δ***1 PH domain chimera and Lyn-tagged PLC***γ* **2 in DT40 cells**

(A) Representation of the constructs encoding the wild-type PLCγ 2 (top), the PLCδ1PH domain chimera of PLCγ 2 (middle) and the Lyn-tagged PLCγ 2 (bottom). The domains within the PI-PLC core structure (the N-terminal PH domain, EF-hands, catalytic domain incorporating X and Y regions and C2 domain) and the domains specific for PLC_Y isoforms indicated as _YSA (the 'split' PH domain, two SH2 domains and SH3 domain) are shown. (B) PLC_γ2 localization in DT40 stable cell lines. Stably transfected DT40 cell lines PLC_γ2−/PLC_γ2 (left), PLC_γ2-/PHδ1PLCγ2 (middle) and PLCγ2−/Lyn–PLCγ2 (right) were analysed by immunofluorescence confocal microscopy using anti-PLCγ2 antibody. Fields of cells and enlarged single cell images are shown. (**C**) Lipid raft compartmentalization of the wild-type, PH domain PLCδ1 chimera and Lyn-tagged PLCγ2 in DT40 cells. Extracts from the stably transfected cells, PLCγ2−/PLCγ2, PLCγ2−/PHδ1PLCγ2, and PLCγ2−/Lyn–PLCγ2, were fractionated on discontinuous sucrose gradients as described in the Experimental section. The fractions (2–5 enriched in detergent insoluble rafts and 9–12 enriched in the detergent-soluble proteins), analysed by Western blotting using antibody against PLCγ2, are shown for all three cell lines (top panels). Fractions containing endogenous chicken Lyn are shown in the bottom panel. (**D**) The DT40 PLCγ 2−/PLCγ 2 cell line was analysed for the presence of the wild-type PLCγ 2 in the pool of fractions 2–5 obtained after fractionation on discontinuous sucrose gradients, subjected to Western blotting using anti-PLC γ 2 antibody (left panel). The analysis of tyrosine phosphorylation was performed using anti-phosphotyrosine (PY) antibodies in samples containing comparable amounts of PLC_Y2 (right panel). Cells were stimulated with 2 mM H₂O₂ for 4 min (lane 1), 10 μ g/ml of M4 antibody for 2 min (lane 2) or not stimulated (lane 3). It is estimated that the phosphorylation of the wild-type PLC_γ2 triggered by M4 represents 25–30% of phosphorylation in the presence of H₂O₂. (**E**) The cell lines PLC_γ2⁻/PHδ1PLC_γ2 (lanes 1 and 2) and BLNK⁻/PHδ1PLC_Y2 (lanes 3 and 4) were analysed for the presence of PLC_Y2 in the pool of fractions 2–5 obtained after fractionation on discontinuous sucrose gradients as described in (**D**). Analysis was performed with H_2O_2 stimulated (lanes 1 and 3) and non-stimulated cells (lanes 2 and 4).

of function and regulation of proteins that interact with the plasma membrane, specific targeting signals, such as the Cterminal sequence of H- and K-Ras (including the CAAX box) and the N-terminal sequences of Src kinases, have been used to achieve constitutive targeting [36,37]. Among PI-PLCs, only the PLC*δ*1 PH domain provides a membrane anchor in the absence of stimulation by binding to PtdIns $(4,5)P_2$ [38,39]. To constitutively target PLC*γ* 2 to the plasma membrane of DT40 cells, we have chosen to replace the PH domain of PLC*γ* 2 with the PLC*δ*1 PH domain that would localize PLC*γ* 2 to the plasma membrane sites where PtdIns(4,5) P_2 substrate is present. We have also chosen the N-terminus of the Src family kinases, known to determine targeting to raft microdomains, as a targeting signal for PLC*γ* 2. In DT40 B-cells, Lyn kinase has been described as constitutively present in the membrane rafts. Within the sequence $M¹GCIKSKGKD¹⁰$ of Lyn, two residues (Gly² and Cys³) are likely to undergo lipid modifications, myristoylation and palmitoylation [36]. The constructs of PLC*γ* 2 containing either PLC*δ*1 PH domain (PH*δ*1PLC*γ* 2) or the N-terminal tag of Lyn (Lyn–PLC*γ* 2) were made (Figure 1A).

The stable cell lines expressing the membrane-targeted constructs of PLC*γ* 2 were first made in PLC*γ* 2-deficient cells (Table 1) to confirm that the constructs were localized to the plasma membrane and that the changes have not resulted in chimeras/tagged proteins that are no longer functional in B-cell signalling. In B-cells, translocation of PLC*γ* 2 requires BLNK, and BLNK-deficient DT40 cells do not support translocation of PLC*γ* 2 [20]. Therefore, the PLC*γ* 2 constructs were also introduced into BLNK-deficient DT40 cells (Table 1) to test their ability to bypass the function of BLNK. As shown in Figure 1(B), the stable cell lines of the targeted constructs (PH*δ*1PLC*γ* 2 and Lyn–PLC γ 2, middle and right panels), unlike the cells containing the wild-type construct of PLC*γ* 2 (PLC*γ* 2, left panel), demonstrated the presence of PLC*γ* 2 in the plasma membrane. Essentially the same results were obtained when the constructs were introduced into PLC*γ* 2-deficient and BLNK-deficient cells, since

Figure 2 Production of Ins(1,4,5)P³ in various DT40 cell lines

Samples of 2×10^6 cells from non-stimulated DT40 cells and DT40 cells stimulated with 2 mM H_2O_2 for 5 min were analysed for $Ins(1,4,5)P_3$ production as described in the Experimental section. The DT40 cell lines were as follows: PLC γ 2-deficient (PLC γ 2-) (1), PLCγ2-deficient cells stably transfected with the wild-type human PLCγ2 (PLCγ2⁻/PLCγ2) (2), PLC γ 2-deficient cells stably transfected with the PLCδ1PH domain chimera of PLC γ 2 (PLCγ 2−/PHδ1PLCγ 2) (3), PLCγ 2-deficient cells stably transfected with the Lyn-tagged PLCγ2 (PLCγ2⁻/Lyn–PLCγ2) (4), BLNK-deficient (BLNK-) (5), BLNK-deficient cells stably transfected with the human BLNK (BLNK−/BLNK) (6), BLNK-deficient cells stably transfected with the wild-type PLC γ 2 (BLNK⁻/PLC γ 2) (7), BLNK-deficient cells stably transfected with the PLCδ1PH domain chimera of PLCγ 2 (BLNK−/PHδ1PLCγ 2) (8) and BLNK-deficient cells stably transfected with the Lyn-tagged PLC γ 2 (BLNK⁻/Lyn–PLC γ 2) (9). Ins(1,4,5) P_3 production in stimulated cells is shown by grey bars. The results are expressed as the means \pm S.D. for three independent experiments performed in duplicate.

endogenous PLC*γ* 2 in BLNK-deficient cells only contributed to the staining in the cytoplasm.

Since the stimulation of B- and T-cells results in enrichment of the wild-type PLC*γ* in specialized plasma membrane microdomains ([9,13] and Figure 1), a further analysis of different DT40 cell lines was performed. To define membrane microdomains where PLC*γ* 2-targeted constructs are present, a separation method designed to isolate membrane rafts was performed (Figure 1C). Comparison was made between stable cell lines (made using PLC*γ* 2-deficient background) expressing the wildtype PLC*γ* 2, the PH*δ*1PLC*γ* 2 chimera or Lyn–PLC*γ* 2. As shown in Figure 1(C), the wild-type PLC*γ* 2 and PH*δ*1PLC*γ* 2 chimera (upper panels) were not present in fractions containing lipid rafts (fractions 2–5), whereas Lyn–PLC*γ* 2 and endogenously present Lyn kinase (lower panels) were clearly present in the membrane raft fractions. Thus, although two targeted constructs of PLC*γ* 2 were present in the plasma membrane, only the Lyn-tagged PLC*γ* 2 construct resulted in the enrichment of PLC*γ* 2 in the raft microdomains in the absence of stimulation. Interestingly, the PH*δ*1PLC*γ* 2 chimera was found in lipid rafts only after stimulation in PLC*γ* 2-deficient cells, but not in BLNK-deficient cells (Figure 1E).

Effects of membrane targeting of PLC*γ* **2 on DT40 responses to BCR cross-linking and H2O2 stress**

Following the BCR stimulation or H_2O_2 stress, phosphorylation of the wild-type PLC*γ* 2 can be readily detected (Figure 1D, right panel) and is accompanied by an increase in PLC activity (Figure 2). The constitutive membrane targeting of PLC*γ* 2, particularly to the rafts where many tyrosine kinases are present, could lead to constitutive phosphorylation and activation PLC*γ* 2.

Analysis of Lyn-targeted PLC*γ* 2, however, demonstrated that it did not contain phosphotyrosine in unstimulated cells (Figure 3B). Stimulation of the stable cell line expressing Lyn–PLC*γ* 2 resulted in phosphorylation of its tyrosine residues, as has been observed for the wild-type PLC*γ* 2 (Figure 3B). Similarly, the appearance of membrane patches, visualized by anti-PLC*γ* 2 antibody, could be detected only after stimulation (Figure 3A). Essentially the same results were obtained when Lyn–PLC*γ* 2 was introduced to BLNK-deficient (Figure 3A) and PLC*γ* 2-deficient cells (results not shown). As previously reported [19–21], in the control cell line where the wild-type PLCγ2 was introduced into BLNKdeficient cells, translocation could not be detected (Figure 3A, bottom panel), whereas the phosphorylation was greatly reduced (in response to H_2O_2 , Figure 3B, right panel) or absent (in response to BCR stimulation, results not shown).

To assess activation of PLC γ 2, the formation of Ins(1,4,5) P_3 was measured in different stable DT40 cell lines after stimulation by BCR cross-linking (using M4 antibody) or stress responses to H_2O_2 . Under the conditions used in the present study, the maximum $Ins(1,4,5)P_3$ production was at about 1 min after addition of M4 and about 5–10 min after addition of H_2O_2 . These time points were used to compare different stable cell lines and demonstrated that the relative responses to M4 and H_2O_2 for a given cell line were similar. The $Ins(1,4,5)P_3$ responses of different cell lines are shown in Figure 2, using H_2O_2 as a stimulus. Analysis of Ins(1,4,5)*P*³ production by PH*δ*1PLC*γ* 2 chimera and Lyn–PLC*γ* 2 in a PLC*γ* 2-deficient background demonstrated that both constructs were functional and could restore the $\text{Ins}(1,4,5)P_3$ generation lacking in PLC*γ* 2-deficient DT40 cells. However, only Lyn–PLC γ 2 was able to restore Ins(1,4,5) P_3 production in DT40 cells deficient in BLNK; the levels of $\text{Ins}(1,4,5)P_3$ produced were similar to those in the stable cell line where human BLNK have been introduced into a BLNK-deficient background. These experiments suggested that the PH*δ*1PLC*γ* 2 chimera had properties of the wild-type protein both in raft-localization after stimulation and the ability to restore $\text{Ins}(1,4,5)P_3$ production only in PLC*γ* 2-deficient background (Figure 1 and 2). In contrast, Lyntagged PLC*γ* 2 can bypass requirements for BLNK by providing more specific membrane-targeting signal resulting in localization of PLC*γ* 2 to membrane rafts.

Since the analysis of $Lyn-PLC\gamma$ ² have not revealed clear differences in BLNK[−] and PLC*γ* 2-deficient cells, further characterization is shown for the BLNK−/Lyn–PLC*γ* 2 cell line in comparison with a control cell line, the wild-type PLC*γ* 2 in PLC*γ* 2-deficient cells (Figure 3). The time course for production of Ins(1,4,5) P_3 is shown in Figure 3(C). The responses to H_2O_2 were similar with some reduction in $\text{Ins}(1,4,5)P_3$ generation (about 20–25%) observed for BLNK−/Lyn–PLC*γ* 2 cell line at earlier time points (Figure 3C, left panel). Transient responses to M4 for the two cell lines were also similar, and again only a small reduction at earlier time points was observed (Figure 3C, right panel). The differences in $Ins(1,4,5)P_3$ production between the cell lines were reflected in Ca^{2+} responses (Figure 3D).

Importance of the SH2 domains and tyrosine residues implicated in phosphorylation for the activation of raft-targeted PLC*γ* **2**

Since the Lyn-targeted PLC*γ* 2 is not constitutively active and bypasses targeting to the membrane alone, it provides a system to test the requirement of the SH2 domains and tyrosine residues (implicated in phosphorylation by Btk) that are specifically related to changes leading to a high rate of $PtdIns(4,5)P_2$ hydrolysis. Therefore, for this analysis, mutations in both SH2 domains or mutations of Tyr⁷⁵³ and Tyr⁷⁵⁹ have been made in the context of Lyn-tagged PLC*γ* 2 (Figure 4A) and the stable cell lines

(A) Immunofluorescence confocal analysis of PLCγ2 localization in PLCγ2 (top panels), BLNK-/Lyn–PLCγ2 (middle panels) and BLNK-/PLCγ2 (bottom panels) was performed, as described in Figure 1, before (left panels) and after (right panels) stimulation. (**B**) PLCγ2 phosphorylation in PLCγ2-deficient cells stably transfected with the wild-type PLCγ2 (PLCγ2−/PLCγ2, PLCγ2−/PLCγ2, lanes 1 and 2) and BLNK-deficient cells stably transfected with the Lyn-tagged PLCγ 2 (BLNK−/Lyn–PLCγ 2, lanes 3 and 4) was analysed before (–) and after (+) stimulation with 2 mM H₂O₂. PLCγ2 was immunoprecipitated from cell extracts using anti-PLCy2 antibody and the Western blotting performed with either anti-PLCy2 antibody (top panels) or anti-phosphotyrosine antibody (α-PY; bottom panels). After the stimulation with M4 antibody, reduction of PLCγ2 phosphorylation in PLCγ2−/PLCγ2DT40 cells was similar to that shown in Figure 1(D); a similar 3–4-fold reduction was observed in BLNK-/Lyn–PLC_γ2, while the phosphorylation in BLNK-/PLC_γ2 could not be detected (results not shown). (**C**) Time-course analysis of lns(1,4,5)P₃ production. Ins(1,4,5)P₃ was measured in extracts prepared from 2 \times 10⁶ cells of BLNK⁻/Lyn–PLCγ2 (\blacktriangle) and PLCγ2⁻/PLCγ2 (\Box) DT40 cell lines. Stimulation was either with 2 mM H₂O₂ (left panel) or 10 µg/ml M4 (right panel) for the indicated times. The results are expressed as the means \pm S.D. for experiments performed in duplicate. (**D**) Ca²⁺ mobilization was measured in Fluo 3/AM-loaded PLC_γ2⁻/PLC_γ2 (1) and BLNK⁻/Lyn–PLC_γ 2 (2) DT40 cells after stimulation with 2 mM H₂O₂ (dark grey) or 10 μg/ml M4 (light grey), as described in the Experimental section. R.F.U., relative fluorescence units.

generated (Table 1). Both constructs (Lyn–PLC $γ$ 2^{R564A/R672A} and Lyn–PLC*γ* 2Y753F*/*Y759F) were expressed at similar levels as Lyn– PLC*γ* 2 and were targeted to the membrane (Figure 4B). As shown in Figure 4(C), phosphorylation of both constructs could be detected; the phosphorylation levels were reduced for Lyn– PLC*γ* 2Y753*/*759F, but not as severely as in the context of nontargeted PLC γ 2 as shown previously [24]. It is possible that by introducing the Lyn-tag, the amount of $PLC\gamma$ ² and/or time that PLC γ ² is exposed to raft-associated kinases may be increased, resulting in further phosphorylation of tyrosine residues other than Tyr753 and Tyr759, known to be accessible to phosphorylation, at least *in vitro* [24,25].

Several previous studies of non-targeted PLC*γ*2 in DT40 cells have demonstrated that both the SH2 domain mutation (R564A/R672A) and Y753F/Y759F mutation have diminished or greatly reduced the ability of PLC*γ* 2 to restore responses in PLC*γ* 2-deficient cells without non-specifically affecting catalytic properties in vitro [19,24,25]. Analysis of $\text{Ins}(1,4,5)P_3$ production at the fixed time-points in cell lines expressing Lyn-tagged PLC*γ* 2 in PLC*γ* 2- or BLNK-deficient background have shown that Lyn– PLC*γ* 2 and also Lyn–PLC*γ* 2R564A*/*R672A can restore responses to M4 antibody or H₂O₂, whereas Lyn–PLC_γ 2^{Y753F/Y759F} could only restore about 20–25% of the $\text{Ins}(1,4,5)P_3$ production observed for other constructs (Figure 5A). The differences between the cell lines have also been confirmed by analysis of Ca^{2+} responses to $M4$ and H_2O_2 (results not shown).

The Ins(1,4,5) P_3 production by Lyn–PLC_γ 2^{R564A/R672A} and Lyn– PLC*γ* 2Y753F*/*Y759F mutants was further analysed in a time-course experiment following stimulation by H_2O_2 (Figure 5B, left panel) or M4 (Figure 5B, right panel). The amount of $\text{Ins}(1,4,5)P_3$ produced in the stable cell line expressing Lyn–PLC*γ* 2Y753F*/*Y759F were greatly reduced. Nevertheless, similar to the control cells and Lyn–PLC γ 2 (see Figures 3 and 6), the responses to H_2O_2 were sustained and those following addition of M4 antibodies were only transient. In the stable cell line expressing Lyn–PLC*γ* 2R564A*/*R672A, the amounts of $\text{Ins}(1,4,5)P_3$ produced at the late time points

Figure 4 Mutations in the SH2 domains and critical tyrosine residues in the context of Lyn-tagged PLC*γ* **2**

(**A**) Representation of the constructs encoding the Lyn-tagged PLCγ 2 incorporating Y753F/ Y759F (upper panel) or R564A/R672A (lower panel) mutations. (**B**) Localization of PLCγ 2 constructs in stably transfected PLCγ2⁻/Lyn–PLCγ2^{R564A/R672A} and PLCγ2⁻/Lyn– PLC_Y 2^{Y753F/Y759F} DT40 cells was analysed by immunofluorescence confocal microscopy using anti-PLC γ 2 antibody. The fields of cells and enlarged single cell images (insets) are shown. (**C**) The cell lines described in (**B**), were also analysed for tyrosine phosphorylation of PLC γ 2 before (-) and after (+) stimulation with H₂O₂ (lanes 1–4). Stimulated PLC γ 2⁻/ Lyn–PLCγ 2 and PLCγ 2−/PLCγ 2 cells are shown for comparison (lanes 5 and 6). After immunoprecipitation using anti-PLC γ 2 antibody, Western blotting was performed with either anti-phosphotyrosine antibody (α -PY; top panel) or anti-PLC_γ2 antibody (bottom panel). The comparison of the ratios of intensities obtained with the two antibodies resulted in an estimate that Lyn–PLCγ2 was phosphorylated about two-fold more than PLCγ2. Phosphorylation of Lyn–PLCγ 2R564A/R674A was similar to Lyn–PLCγ 2, whereas Lyn–PLCγ 2Y753F/Y759F was reduced to about 30 % of Lyn–PLC γ ^{2R564A/R674A}. The fold reduction after M4 stimulation for Lyn–PLC_Y 2^{R564A/R672A} and Lyn–PLC_Y 2^{Y753F/Y759F} constructs was as described for the wild-type PLC γ 2 in Figure 1(D).

following H_2O_2 stimulation were reduced; instead of sustained production of $\text{Ins}(1,4,5)P_3$, the response was transient and completely diminished after 10 min (Figure 5B, left panel).

The results described above suggest that within the membrane-raft-targeted construct of PLC*γ* 2, the stimulation of PtdIns $(4,5)P_2$ hydrolysis requires the presence and, presumably, phosphorylation of Tyr⁷⁵³ and Tyr⁷⁵⁹. In contrast, the SH2 domains appear to have a less critical role, but could be important for sustained activation of PLC*γ* 2.

Involvement of Btk, Syk and PI3K in activation of the raft-targeted PLC*γ* **2**

In DT40 cells deficient in Btk or Syk tyrosine kinase, the BCR stimulation or H_2O_2 treatment resulted in reduced or diminished production of Ins $(1,4,5)P_3$ and Ca²⁺ responses [31,32,40,41]. It is possible that these kinases could contribute to both translocation and activation of PLC*γ* 2. To test the involvement of Syk and Btk in the activation of PLC*γ* 2 further, Lyn–PLC*γ* 2 construct was introduced in Btk- or Syk-deficient cells (Table 1). As expected, the Lyn–PLC*γ* 2 was present in the plasma membrane of generated stable cell lines (Figure 6A).

Analysis of Ins(1,4,5)*P*³ production in Syk−/Lyn–PLC*γ* 2 and Btk⁻/Lyn–PLC γ 2 cell lines demonstrated some response to H_2O_2 and M4 stimulation (Figure 6C), which, in agreement with previous observations [31,32,40,41], could not be detected in Syk- or Btk-deficient cells (results not shown) and were mediated by endogeous non-tagged PLC*γ* 2. However, as shown in Figure 6(C), these responses were different from those in the control cell line (PLC γ 2[−]/PLC γ 2). Stimulation by H₂O₂ resulted in delayed and somewhat reduced Ins(1,4,5)*P*³ production (Figure 6C, left panel). Under these conditions Lyn–PLC*γ* 2 was phosphorylated (Figure 6B), most likely by tyrosine kinases present in the rafts and due to the inhibition of protein phosphotyrosine phosphatases by H_2O_2 . However, when stimulation through BCR cross-linking was analysed, the phosphorylation of Lyn–PLC*γ* 2 was hardly detectable and this construct was very poor in restoring cellular responses (Figures 6B and 6C). The production of $Ins(1,4,5)P_3$ in both cell lines, Syk−/Lyn–PLC*γ* 2 and Btk−/Lyn–PLC*γ* 2, was greatly reduced and transient (Figure 6C, right panel). These results demonstrated that both Syk and Btk tyrosine kinases are required for activation of PLC*γ* 2 under these more physiological conditions, and further supported previous findings that their activation in BCR signalling directly or indirectly results in PLC*γ* 2 phosphorylation.

Analysis of DT40 cells deficient in PI3K suggested an involvement of this enzyme in stimulation of PLC*γ* 2 activity [42]. Previous experiments have also suggested that the PI3K product, PtdIns(3,4,5) P_3 , could have several links with PLC γ 2, the most important being the involvement in translocation/stimulation of Btk [43]. Therefore, it would be expected that the inhibition of PI3K by LY294002 or wortmannin have a similar effect as Btk deficiency. The roles of Btk and PI3K, however, seem to be somewhat different in signalling through the BCR compared with H_2O_2 -induced stress. It has been reported that inhibition of PI3K by wortmannin completely abolished Ca^{2+} mobilization in the wild-type DT40 cells stimulated by the BCR cross-linking and only reduced (up to 50%) the Ca^{2+} responses to H_2O_2 stress; also, only in response to H_2O_2 could the inhibition be overcome by Btk over-expression [30]. As shown in Figure 7(B), the analysis of PLC*γ* 2−/PLC*γ* 2 control cells is in agreement with the previous observation using the wild-type DT40 cells [30], and demonstrated the reduction (20–25 %) of $\text{Ins}(1,4,5)P_3$ production by H_2O_2 (Figure 7B, left panel) and complete inhibition of responses to M4 (Figure 7B, right panel) in the presence of either LY294002 or wortmannin. The same differences were observed using BLNK−/Lyn–PLC*γ* 2 cells (Figure 7C) demonstrating that effects of PI3K inhibitors do not require the presence of BLNK and that involvement of PI3K in BCR signalling may be related to activation rather than translocation of PLC*γ* 2, since it cannot be bypassed by Lyn targeting.

DISCUSSION

In the present study, we have described the analysis of regulation of PLC*γ* 2 in B-cell signalling by generating a number of DT40 Bcell lines which expressed various PLC*γ* 2 constructs, membranetargeted and lacking specific functional domains or residues, in a DT40 cell background deficient in different signalling

Figure 5 Analysis of Ins(1,4,5)P₃ production by Lyn–PLC_Y2, Lyn–PLC_Y2^{Y753F/Y759F} and Lyn–PLC_Y2^{R564A/R672A} in various DT40 cell lines

(**A**) Ins(1,4,5)P³ generation in BLNK- and PLCγ 2-deficient cells stably transfected with the Lyn-tagged constructs, Lyn–PLCγ 2, Lyn–PLCγ 2Y753F/Y759F and Lyn–PLCγ 2R564A/R672A, was measured in response to stimulation by H2O2 for 3 min (left panel) and M4 antibody for 0.6 min (right panel) as described in the legend for Figure 3. The following cell lines were analysed: PLCγ2−/Lyn–PLCγ2 (1), BLNK−/Lyn–PLCγ 2 (2), PLCγ 2−/Lyn–PLCγ 2Y753F/Y759F (3), BLNK−/Lyn–PLCγ 2Y753F/Y759F (4), PLCγ 2−/Lyn–PLCγ 2R564A/R672A (5) and BLNK−/Lyn–PLCγ 2R564A/R672A (6). Ins(1,4,5)P³ generation in stimulated cells is shown by dark (H₂O₂) and light (M4) grey bars. The results are expressed as the means±S.D. for three independent experiments performed in duplicate.
(B) Time-course analysis of Ins(1, (right panel) stimulation. The results are expressed as the means \pm S.D. for experiments performed in duplicate.

components. The results support a two-step model: the membrane targeting, specifically to the lipid rafts, and subsequent activation of the enzyme. These steps require interaction with different signalling components and involve different regions of PLC*γ* 2.

The importance of the lipid rafts in PLC*γ* signalling has been addressed in this and several previous studies [12–15,35,44]. In response to different extracellular signals (e.g. stimulation of EGF receptor, collagen receptor glycoprotein VI, TCR and BCR), at least a fraction of PLC*γ* translocates to the lipid rafts [12–15]. In DT40 B-cells, a small but significant portion of PLC γ ² is translocated to this structure; this has also been observed for some other components including BLNK, Btk and more recently, Cbl-b [35,44]. Our studies in DT40 cells provide evidence that the PLC γ 2 targeting to the lipid rafts is essential for signalling by this isoform. Unlike targeting mediated through the PtdIns $(4,5)P_2$ binding by the PLC δ 1 PH domain chimera that results in general membrane targeting without enrichment in rafts, the PLC*γ* 2-containing Lyn-targeting sequences was specifically present in these structures and, more importantly, capable of restoring signalling in BLNK-deficient cells (Figures 1 and 2). Although some results suggest that the substrate for PI-PLC, PtdIns $(4,5)P_2$, is more abundant in rafts [45], at least in B-cells this is not sufficient for the specific targeting. Furthermore, recent studies in cells using the PLC*δ*1PH domain as a probe, suggest a similar density of PtdIns $(4,5)P_2$ in the raft (caveolein)-containing

and other areas of the plasma membrane [46]. Targeting to the rafts therefore may not be related to the substrate access by PLC*γ* 2, but to proximity to molecules such as Syk and Btk tyrosine kinases, known to be recruited to the rafts [14,47] and required for PLC*γ* 2 signalling in B-cells [31,32,40,41]. Interestingly, the Lyn-tagged PLC*γ* 2 was not constitutively phosphorylated and activated (Figures 2 and 3B).

Consistent with the results from the present study (Figures 1 and 2), previous experiments using a different membranetargeting PLC*γ* 2-chimera (not fully active, most likely due to intramolecular constrains and folding problems of the construct) have shown a potential of this targeted molecule to partially restore at least some functions of BLNK [19,20]. Although not analysed directly, these studies have also indicated the importance of specific targeting. More recent work in T-cells using targeted construct of PLC*γ* 1 containing the N-terminus of Src kinase Fyn, similar to the Lyn–PLC*γ* 2 construct described in the present study, have demonstrated the presence of this construct in the lipid rafts [34]. Furthermore, Fyn–PLC*γ* 1 could function without interacting with the adapter Lat and also in cells deficient in another adapter protein, Slp-76. However, in contrast to observations in B-cells, Fyn-PLC*γ* 1 was constitutively phosphorylated and implicated in constitutive Ca^{2+} -dependent increase of transcription [34]. This difference could reflect different tyrosine kinases involved in phosphorylation of two

Figure 6 Analysis of the involvement of Btk and Syk in activation of Lyn-targeted PLC*γ* **2**

(A) Btk- and Syk-deficient cells stably transfected with Lyn-targeted PLCγ2, Btk[−]/Lyn–PLCγ2 (left panel) and Syk⁻/Lyn–PLCγ2 (right panel), were analysed for localization of PLCγ2 constructs by immunofluorescence confocal microscopy. (**B**) The detection of PLCγ2 phosphorylation in the PLCγ2−/Lyn–PLCγ2 (lanes 1 and 2), Btk⁻/Lyn–PLCγ2 (lanes 3 and 4) and Syk⁻/Lyn–PLCγ2 (lanes 5 and 6) DT40 cell lines was performed before (-) and after (+) H₂O₂ stimulation. After immunoprecipitation of PLC_γ2, Western blotting was performed using anti-phosphotyrosine (α -PY; upper panels) and anti-PLCγ2 (lower panels) antibody. It was estimated that the phosphorylation of Lyn–PLCγ2 in Btk- and Syk-deficient cells was reduced 50–60% compared with PLCγ2-deficient background. The M4 stimulation (lanes 7-9) was performed in a separate experiment with the control cell line having the normal difference in phosphorylation between H₂O₂ and M4, described in Figure 1(D). (C) Ins(1,4,5)P₃ generation at different time points after stimulation with H₂O₂ (left panel) and M4 antibody (right panel) was analysed in Btk−/Lyn–PLCγ2 (□) and Syk−/Lyn–PLCγ2 (\triangle) cells and compared with the control cell line PLCγ2⁻/PLCγ2 (○).

PLC*γ* isoforms or a more stringent regulation of PLC*γ* -directed tyrosine kinase activity in resting DT40 cells compared with a specific T-cell line chosen for studies of T-cell signalling.

The membrane-targeted Lyn–PLC*γ* 2 was used to further define post-targeting events leading to PLC activation and to analyse which domains of $PLC\gamma2$ and which signalling components are required specifically for this step. Our results demonstrated different roles for the SH2 domains and specific tyrosine residues (Tyr753 and Tyr759) in the context of Lyn–PLC*γ* 2 (Figures 4 and 5). The functional SH2 domains were only required to support prolonged $\text{Ins}(1,4,5)P_3$ production, whereas the presence of specific tyrosine residues (Tyr⁷⁵³ and Tyr⁷⁵⁹) was essential to fully restore responses by Lyn–PLC γ 2 to BCR cross-linking and H₂O₂.

In previous attempts to study requirements for the high rate of PtdIns(4,5)*P*² hydrolysis by PLC*γ* 1 separately from the requirements for translocation, an *in vitro* system using substrate/ Triton X-100 mixed micelles has been developed [48,49]. In this system, the difference in activity between phosphorylated and non-phosphorylated PLC*γ* 1 have been observed after isolation of PLC*γ* 1 from cells, supporting the importance of phosphorylation in stimulation of PLC activity [48]. Using a similar system, differences have been shown between non-phosphorylated and PLC*γ* 2 phosphorylated *in vitro*, rather than in cells [50]. Nevertheless, studies of different DT40 stable cell lines have shown that mutations of several tyrosine residues introduced separately and the double mutation Y753F/Y759F of PLC*γ* 2, reduce or abolish Ca^{2+} responses to the BCR cross-linking and H_2O_2 [24,25]. Further experiments have also suggested that Y753F/Y759F mutation did not affect translocation [24]. Consistent with these previous findings, the results presented in the present study (Figures 3 and 4) show that the membrane targeting can not bypass the requirement for these specific tyrosine residues. In addition, several other observations (Figure 6) suggest the importance of tyrosine phosphorylation. One of the effects of Lyn-targeting of PLC*γ* 2 is that this construct becomes more readily phosphorylated than the wild-type PLC γ 2, in particular following H₂O₂ stimulation that potently inhibits protein tyrosine phosphatases. This phosphorylation of Lyn–PLC*γ* 2 occurs even in the absence

Figure 7 Effects of PI3K inhibitors, LY294002 and wortmannin

(**A**) Diagram showing inhibition of PI3K by LY294002 and wortmannin in the context of BCR-mediated signalling. The diagram is based on recent reviews [10,11]. (**B**) The control DT40 cell line PLCγ2−/PLCγ2 was either untreated (1) or incubated with 50 μ M LY294002 (2) or 100 nM wortmannin (3) for 30 min. Ins(1,4,5)P₃ present in the cell extracts was measured before and after stimulation with either H₂O₂ for 3 min (left panel) or M4 antibody for 0.6 min (right panel). Ins(1,4,5)P₃ production in stimulated cells is shown by dark (H₂O₂) and light (M4) grey bars. The results are expressed as the means +− S.D. for three independent experiments performed in duplicate. (**C**) The same experiment as described in (**B**) was performed using BLNK−/Lyn–PLC^γ ² cell line.

of Btk and Syk, presumably by some other kinases present in rafts, and is accompanied by activation of Lyn–PLC*γ* 2.

Previous studies of the PLC*γ* 1 SH2 domains have suggested that these domains could be involved not only in translocation, but also in PLC activation [1–3]. For example, binding of tyrosinephosphorylated peptides, corresponding to the PLC*γ* 1-binding sites in the EGF receptor, induced conformational changes of recombinant PLC*γ* 1 and resulted in an increase of PLC activity *in vitro* [49]. Since the suggested binding partner for the PLC*γ* 2 SH2 domains is the adapter protein BLNK, the PLC*γ* 2–BLNK interactions could have a similar effect. Our results using Lyntargeted PLC*γ* 2 (Figures 2, 3 and 5), however, do not support this possibility and show that neither the SH2 domain mutations nor BLNK deficiency have a significant effect on Lyn–PLC*γ* 2 signalling following the BCR cross-linking. Furthermore, in response to H_2O_2 stress, the effects of the SH2 mutations and BLNK deficiency are quite different; only in the case of SH2 domain mutations were the prolonged responses to H_2O_2 affected. Similar observations in Syk-deficient and Btk-deficient cells (Figure 6) do not favour Syk or Btk (the latter previously implicated in sustained substrate hydrolysis) as components responsible for the SH2 domain-mediated effects on prolonged activation. When considering allosteric regulation through the SH2 domain binding, there is also a possibility that the interactions may occur intramolecularly between phosphorylated tyrosines in PLC_γ2 (Tyr⁷⁵³, Tyr759 or others) and one of its SH2 domains. Regardless of the identity of phosphotyrosine residues that bind the SH2 domains, this interaction could stabilize an activated form of PLC*γ* 2 (which could be caused by phosphorylation of critical tyrosine residues) and/or protect the phosphorylated tyrosines from the

action of phosphatases, thus underlying the observed requirement in prolonged activation.

Analysis of DT40 cells revealed a number of components that contribute to PLC_V2 signalling in this system, including Syk, Btk and PI3K; the requirements for Btk and PI3K are less stringent under some conditions [30–32,40–42,51]. Further studies in this and other systems suggested that the requirements for these components in $PLC\gamma2$ signalling could reflect their involvement at several steps leading to PLC responses and could also include both indirect effects and direct interactions with PLC*γ* 2. For example, Syk kinase is not only required for phosphorylation of BLNK [20,21,24], but also contributes to activation of Btk and PI3K [52,53]. In the case of Btk, in addition to the suggested role in direct phosphorylation of several tyrosine residues in PLC γ 2 [24,25], this protein may be an important structural component of a scaffold required for the assembly of BCR signalling complexes [54]. The requirement for PI3K in PLC*γ* 2 signalling in B-cells could be due to its involvement in the regulation of Btk [43]. However, the link between PI3K and PLC*γ* isoforms could be more direct and affect either translocation or PLC activation [5–7]. Our results (Figures 6 and 7) show that Syk and Btk proteins and PI3K activity are all required for the activation step of the raft targeted PLC*γ* 2 in response to BCR cross-linking. Interestingly, stimulation by H_2O_2 , accompanied by enhanced phosphorylation of the Lyn–PLC*γ* 2, can partially restore responses in Btk- and Syk-deficient cells by this targeted construct, suggesting that their effects at the activation step are at least in part related to phosphorylation of PLC*γ* 2. In contrast with our present study, the analysis of Fyn–PLC*γ* 1 in T-cell signalling have not supported the role of the Syk family kinase Zap-70 (zeta-associated protein 70) or the production of PtdIns $(3,4,5)P_3$ in the regulation of PLC activity of this construct [34]. However, it is not clear whether these differences reflect selected cell types, where the lipid-raft targeting is coupled or uncoupled with constitutive phosphorylation and activation, or physiological differences between regulation of PLC*γ* 1 activity in T-cells and regulation of PLC*γ* 2 in B-cells.

The results described in the present study, together with previous observations [14,19,20], support the important role of the lipid-raft targeting as a first step in regulation of PLC*γ* 2. They also suggest that post-targeting events, resulting in fully active PLC, involve additional modifications and interactions that in the BCR signalling require specific tyrosine residues that are implicated in the phosphorylation of PLC*γ* 2 and the activation of Syk, Btk and PI3K.

We are grateful to H. Patterson for help with immunostaining and confocal microscopy, and T. Kurosaki for the chicken anti-Lyn antibody. This work is funded by an Institute of Cancer Research studentship to R. R. and a Cancer Research UK grant to M. K.

REFERENCES

- 1 Katan, M. (1998) Families of phosphoinositide-specific phospholipase C: structure and function. Biochim. Biophys. Acta **1436**, 5–17
- 2 Rebecchi, M. J. and Pentyala, S. N. (2000) Structure, function, and control of phosphoinositide-specific phospholipase C. Physiol. Rev. **80**, 1291–1335
- 3 Rhee, S.-G. (2001) Regulation of phosphoinositide-specific phospholipase C. Annu. Rev. Biochem. **70**, 281–312
- 4 Wilde, J. I. and Watson, S. P. (2001) Regulation of phospholipase C_V isoforms in haematopoietic cells: why one, not the other? Cell Signal. **13**, 691–701
- 5 Falasca, M., Logan, S. K., Lehto, V. P., Baccante, G., Lemmon, M. A. and Schlessinger, J. (1998) Activation of phospholipase C γ by PI 3-kinase-induced PH domain-mediated membrane targeting. EMBO J. **17**, 414–422
- 6 Rameh, L. E., Rhee, S. G., Spokes, K., Kazlauskas, A., Cantley, L. C. and Cantley, L. G. (1998) Phosphoinositide 3-kinase regulates phospholipase Cγ -mediated calcium signaling. J. Biol. Chem. **273**, 23750–23757
- 7 Bae, Y. S., Cantley, L. G., Chen, C. S., Kim, S. R., Kwon, K. S. and Rhee, S. G. (1998) Activation of phospholipase C- γ by phosphatidylinositol 3,4,5-trisphosphate. J. Biol. Chem. **273**, 4465–4469
- 8 Tvorogov, D. and Carpenter, G. (2002) EGF-dependent association of phospholipase C-γ 1 with c-Cbl. Exp. Cell Res. **277**, 86–94
- 9 Kane, L. P., Lin, J. and Weiss, A. (2000) Signal transduction by the TCR for antigen. Curr. Opin. Immunol. **12**, 242–249
- 10 Kurosaki, T., Maeda, A., Ishiai, M., Hashimoto, A., Inabe, K. and Takata, M. (2000) Regulation of PLCγ 2 pathway in B cells. Immunol. Rev. **176**, 19–29
- 11 Kurosaki, T. (2002) Regulation of B cell signal transduction by adaptor proteins. Nat. Rev. Immunol. **2**, 354–363
- 12 Wang, X. J., Liao, H. J., Chattopadhyay, A. and Carpenter, G. (2001) EGF-dependent translocation of green fluorescent protein-tagged PLC- γ 1 to the plasma membrane and endosomes. Exp. Cell Res. **267**, 28–36
- 13 Pierce, S. K. (2002) Lipid rafts and B-cell activation. Nat. Rev. Immunol. **2**, 96–105
- 14 Aman, M. J. and Ravichandran, K. S. (2000) A requirement for lipid rafts in B cell receptor induced Ca2⁺ flux. Curr. Biol. **10**, 393–396
- 15 Xavier, R., Brennan, T., Li, Q., McCormack, C. and Seed, B. (1998) Membrane compartmentation is required for efficient T cell activation. Immunity **8**, 723–732
- 16 Chung, J. B., Baumeister, M. A. and Monroe, J. G. (2001) Differential sequestration of plasma membrane-associated B cell antigen receptor in mature and immature B cells into glycosphingolipid-enriched domains. J. Immunol. **166**, 736–740
- 17 Sproul, T. W., Malapati, S., Kim, J. and Pierce, S. K. (2000) B cell antigen receptor signaling occurs outside lipid rafts in immature B cells. J. Immunol. **165**, 6020–6023
- 18 Matsuda, M., Paterson, H. F., Rodriguez, R., Fensome, A. C., Ellis, M. V., Swann, K. and Katan, M. (2001) Real time fluorescence imaging of PLC γ translocation and its interaction with the epidermal growth factor receptor. J. Cell Biol. **153**, 599–612
- 19 Ishiai, M., Sugawara, H., Kurosaki, M. and Kurosaki, T. (1999) Association of phospholipase C-γ 2 Src homology 2 domains with BLNK is critical for B cell antigen receptor signaling. Immunol. J. **163**, 1746–1749
- 20 Ishiai, M., Kurosaki, M., Pappu, R., Okawa, K., Ronko, I., Fu, C., Shibata, M., Iwamatsu, A., Chan, A. C. and Kurosaki, T. (1999) BLNK is required for coupling Syk to PLCγ 2 and Rac1-JNK in B cells. Immunity **10**, 117–125
- 21 Fu, C., Turck, C. W., Kurosaki, T. and Chan, A. C. (1998) BLNK: a central linker protein in B cell activation. Immunity **9**, 93–103
- 22 Bobe, R., Wilde, J. I., Maschberger, P., Venkateswarlu, K., Cullen, P. J., Siess, W. and Watson, S. P. (2001) Phosphatidylinositol 3-kinase-dependent translocation of phospholipase $C\gamma$ 2 in mouse megakaryocytes is independent of Bruton tyrosine kinase translocation. Blood **97**, 678–684
- 23 Kim, H.-K., Kim, J.-W., Zilberstein, A., Margolis, B., Kim, J.-G., Schlessinger, J. and Rhee, S.-G. (1991) PDGF stimulation of inositol phospholipid hydrolysis requires PLC-γ 1 phophorylation on tyrosine residues 783 and 1254. Cell (Cambridge, Mass.) **65**, 435–441
- 24 Rodriguez, R., Matsuda, M., Perisic, O., Bravo, J., Paul, A., Jones, N. P., Light, Y., Swann, K., Williams, R. L. and Katan, M. (2001) Tyrosine residues in PLCγ 2 essential for the enzyme function in B cell signaling. J. Biol. Chem. **276**, 47982–47992
- 25 Watanabe, D., Hashimoto, S., Ishiai, M., Matsushita, M., Baba, Y., Kishimoto, T., Kurosaki, T. and Tsukada, S. (2001) Four tyrosine residues in PLC_V2 , identified as Btk-dependent phosphorylation sites, are required for B cell antigen receptor-coupled calcium signaling. J. Biol. Chem. **276**, 38595–38601
- 26 Sekiya, F., Bae, Y. S. and Rhee, S.-G. (1999) Regulation of phospholipase C isozymes: activation of phospholipase $C-\gamma$ in the absence of tyrosine-phosphorylation. Chem. Phys. Lipids **98**, 3–11
- 27 Horstman, D. A., DeStefano, K. and Carpenter, G. (1996) Enhanced phospholipase C-γ 1 activity produced by association of independently expressed X and Y domain polypeptides. Proc. Natl. Acad. Sci. U.S.A. **23**, 7518–7521
- 28 Fernald, A. W., Jones, G. A. and Carpenter, G. (1994) Limited proteolysis of phospholipase $C-\gamma$ 1 indicates stable association of X and Y domains with enhanced catalytic activity. Biochem. J. **302**, 503–509
- 29 Homma, Y. and Takenawa, T. (1992) Inhibitory effect of Src homology (SH) 2/SH3 fragments of phospholipase C-γ on the catalytic activity of phospholipase C isoforms. Identification of a novel phospholipase C inhibitor region. J. Biol. Chem. **267**, 21844–218449
- 30 Qin, S., Stadtman, E. R. and Chook, P.-B. (2000) Regulation of oxidative stress-induced calcium release by phosphatidylinositol 3-kinase and Bruton's tyrosine kinase in B cells. Proc. Natl. Acad. Sci. U.S.A. **97**, 7118–7123
- 31 Qin, S., Inazu, T., Takata, M., Kurosaki, T., Homma, Y. and Yamamura, H. (1996) Cooperation of tyrosine kinases p72^{syk} and p53/56^{lyn} regulates calcium mobilization in chicken B cell oxidant stress signaling. Eur. J. Biochem. **236**, 443–449
- 32 Qin, S. and Chock, P. B. (2001) Bruton's tyrosine kinase is essential for hydrogen peroxide-induced calcium signaling. Biochemistry **40**, 8085–8091
- 33 Petrie, R. J., Schnetkamp, P. P., Patel, K. D., Awasthi-Kalia, M. and Deans, J. P. (2000) Transient translocation of the B cell receptor and Src homology 2 domain-containing inositol phosphatase to lipid rafts: evidence toward a role in calcium regulation. J. Immunol. **165**, 1220–1227
- 34 Veri, M.-C., DeBell, K. E., Seminario, M.-C., DiBaldasarre, A., Reischl, I., Rawat, R., Graham, L., Noviello, C., Rellahan, B. L., Miscia, S. et al. (2001) Membrane raft dependent regulation of PLCγ 1 activation in T Lymphocytes. Mol. Cell. Biol. **21**, 6939–6950
- 35 Ishiai, M., Kurosaki, M., Inabe, K., Chan, A. C., Sugamura, K. and Kurosaki, T. (2000) Involvement of LAT, Gads, and Grb2 in compartmentation of SLP-76 to the plasma membrane. J. Exp. Med. **192**, 847–856
- 36 Resh, M. D. (1994) Myristylation and palmitylation of Src family members: The fats of the matter. Cell (Cambridge, Mass.) **76**, 411–413
- 37 Reuther, G. W., Buss, J. E., Quilliam, L. A., Clark, G. J. and Der, C. J. (2000) Analysis of function and regulation of proteins that mediate signal transduction by use of lipidmodified plasma membrane-targeting sequences. Methods Enzymol. **327**, 331–350
- 38 Katan, M. and Allen, V. L. (1999) Modular PH and C2 domains in membrane attachment and other functions. FEBS Lett. **452**, 36–40
- 39 Balla, T. and Varnai, P. (2002) Visualizing cellular phosphoinositide pools with GFP-fused protein-modules. Sci. STKE **125**, PL3
- 40 Takata, T., Sabe, H., Hata, A., Inazu, T., Homma, Y., Nukuda, T., Yamamura, H. and Kurosaki, T. (1994) Tyrosine kinases Lyn and Syk regulate B cell receptor coupled Ca^{2+} mobization through distinct pathways. EMBO J. **13**, 1341–1349
- 41 Takata, M. and Kurosaki, T. (1996) A role for a Bruton's tyrosine kinase in B cell antigen receptor-mediated activation of phospholipase Cγ 2. J. Exp. Med. **184**, 31–40
- Inabe, K., Ishiai, M., Scharenberg, A. M., Freshney, N., Downward, J. and Kurosaki, T. (2002) Vav3 modulates B cell receptor responses by regulating phosphoinositide 3 kinase activation. J. Exp. Med. **195**, 189–200
- 43 Scharenberg, A. M., El-Hillal, O., Fruman, D. A., Beitz, L. O., Li, Z., Lin, S., Gout, I., Cantley, L. C., Rawlings, D. J. and Kinet, J. P. (1998) Phosphatidylinositol-3,4,5-triphosphate (PtdIns-3,4,5-P3)/Tec kinase-dependent calcium signaling pathway: a target for SHIP-mediated inhibitory signals. EMBO J. **17**, 1961–1972
- 44 Yasuda, T., Tezuka, T., Maeda, A., Inazu, T., Yamanashi, Y., Gu, H., Kurosaki, T. and Yamamoto, T. (2002) Cbl-b positively regulates Btk-mediated activation of phospholipase C-γ 2 in B cells. J. Exp. Med. **196**, 51–63
- 45 Pike, L. J. and Casey, L. (1996) Localization and turnover of phosphatidylinositol 4,5-bisphosphate in caveolin-enriched membrane domains. J. Biol. Chem. **271**, 26453–26456
- 46 Watt, S. A., Kular, G., Fleming, I. N., Downes, C. P. and Lucocq, J. M. (2002) Subcellular localization of phosphatidylinositol 4,5-bisphosphate using the pleckstrin homology domain of phospholipase C δ1. Biochem. J. **363**, 657–666
- 47 Guo, B., Kato, R. M., Garcia-Lloret, M., Wahl, M. I. and Rawlings, D. J. (2000) Engagement of the human pre-B-cell receptor generates a lipid raft dependent calcium signaling complex. Immunity **13**, 243–253
- 48 Wahl, M. I., Jones, G. A., Nishibe, S., Rhee, S. G. and Carpenter, G. (1992) Growth factor stimulation of phospholipase $C-\gamma$ 1 activity. Comparative properties of control and activated enzymes. J. Biol. Chem. **267**, 10447–10456

Received 14 November 2002/19 May 2003; accepted 3 June 2003 Published as BJ Immediate Publication 3 June 2003, DOI 10.1042/BJ20021778

- 49 Koblan, K. S., Schaber, M. D., Edwards, G., Gibbs, J. B. and Pompliano, D. L. (1995) Src-homology 2 (SH2) domain ligation as an allosteric regulator: modulation of phosphoinositide-specific phospholipase Cγ 1 structure and activity. Biochem. J. **305**, 745–751
- 50 Ozdener, F., Dangelmaier, C., Ashby, B., Kunapuli, S. P., and Daniel, J. L. (2002) Activation of phospolipase Cγ 2 by tyrosine phosphorylation. Mol. Pharmacol. **62**, 672–679
- 51 Tomlinson, M. G., Kurosaki, T., Berson, A. E., Fujii, G. H., Johnston, J. A. and Bolen, J. B. (1999) Reconstitution of Btk signaling by the atypical Tec family tyrosine kinases Bmx and Txk. J. Biol. Chem. **274**, 13577–13585
- 52 Baba, Y., Hashimoto, S., Matsushita, M., Watanabe, D., Kishimoto, T., Kurosaki, T. and Tsukada, S. (2001) BLNK mediates Syk-dependent Btk activation. Proc. Natl. Acad. Sci. U.S.A. **98**, 2582–2586
- 53 Beitz, L. O., Fruman, D. A., Kurosaki, T., Cantley, L. C. and Scharenberg, A. M. (1999) Syk is upstream of phosphoinositide 3-kinase in B cell receptor signaling. J. Biol. Chem. **274**, 32662–32666
- 54 Tomlinson, M. G., Woods, D. B., McMahon, M., Wahl, M. I., Witte, O. N., Kurosaki, T., Bolen, J. B. and Johnston, J. A. (2001) A conditional form of Bruton's tyrosine kinase is sufficient to activate multiple downstream signaling pathways via PLC γ 2 in B cells. BMC Immunol. **2**, 4